Loading clinical trials...
Loading clinical trials...
Response of Fatty Liver to Lifestyle Modification in Psoriasis Patients
Several recent reports have shown an increased prevalence of nonalcoholic fatty liver disease (NAFLD) in those with psoriasis, which may reflect the increased occurrence of metabolic syndrome in this patient population.
the recruitment of 60 fatty live men with chronic disease, psoriasis, will be classified to lifestyle modification group (foe 12 weeks, this patients will take supervised energy or diet restriction program plus their usual immunosuppressive drugs ) and control group will continue their drug program only)
Age
18 - 80 years
Sex
MALE
Healthy Volunteers
No
Faculty of Physical Therapy Cairo University
Giza, Dokki, Egypt
Start Date
September 13, 2021
Primary Completion Date
March 15, 2022
Completion Date
March 15, 2022
Last Updated
November 18, 2021
60
ESTIMATED participants
lifestyle modification
OTHER
usual lifestyle
OTHER
Lead Sponsor
Cairo University
NCT02815891
NCT07449234
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07237750